Practice guideline update recommendations summary: Disorders of consciousness

Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research

Joseph T. Giacino, PhD, Douglas I. Katz, MD, Nicholas D. Schiff, MD, John Whyte, MD, PhD, Eric J. Ashman, MD, Stephen Ashwal, MD, Richard Barbano, MD, PhD, Flora M. Hammond, MD, Steven Laureys, MD, PhD, Geoffrey S.F. Ling, MD, Risa Nakase-Richardson, PhD, Ronald T. Seel, PhD, Stuart Yablonski, MD, Thomas S.D. Getchius, Gary S. Gronseth, MD, and Melissa J. Armstrong, MD

Neurology® 2018;00:1-11. doi:10.1212/WNL.0000000000005926

Abstract

Objective
To update the 1995 American Academy of Neurology (AAN) practice parameter on persistent vegetative state and the 2002 case definition on minimally conscious state (MCS) and provide care recommendations for patients with prolonged disorders of consciousness (DoC).

Methods
Recommendations were based on systematic review evidence, related evidence, care principles, and inferences using a modified Delphi consensus process according to the AAN 2011 process manual, as amended.

Recommemations
Clinicians should identify and treat confounding conditions, optimize arousal, and perform serial standardized assessments to improve diagnostic accuracy in adults and children with prolonged DoC (Level B). Clinicians should counsel families that for adults, MCS (vs vegetative state [VS]/unresponsive wakefulness syndrome [UWS]) and traumatic (vs nontraumatic) etiology are associated with more favorable outcomes (Level B). When prognosis is poor, long-term care must be discussed (Level A), acknowledging that prognosis is not universally poor (Level B). Structural MRI, SPECT, and the Coma Recovery Scale–Revised can assist prognostication in adults (Level B); no tests are shown to improve prognostic accuracy in children. Pain always should be assessed and treated (Level B) and evidence supporting treatment approaches discussed (Level B). Clinicians should prescribe amantadine (100–200 mg bid) for adults with traumatic VS/UWS or MCS (4–16 weeks post injury) to hasten functional recovery and reduce disability early in recovery (Level B). Family counseling concerning children should acknowledge that natural history of recovery, prognosis, and treatment are not established (Level B). Recent evidence indicates that the term chronic VS/UWS should replace permanent VS, with duration specified (Level B). Additional recommendations are included.

Correspondence
American Academy of Neurology
guidelines@aan.com

Related Articles
Comprehensive systematic review update summary: Disorders of consciousness: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research

Ethical, palliative, and policy considerations in disorders of consciousness

Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

This research was supported through a memorandum of understanding between the American Academy of Neurology, the American Congress of Rehabilitation Medicine, and the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR). In 2014, NIDILRR was moved from the US Department of Education to the Administration for Community Living of the US Department of Health and Human Services, and was renamed the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR). This article does not reflect the official policy or opinions of NIDILRR or HHS and does not constitute an endorsement by NIDILRR, HHS, or other components of the federal government.

Approved by the AAN Guideline Development, Dissemination, and Implementation Subcommittee on October 21, 2017; by the AAN Practice Committee on April 9, 2018; by the American Congress of Rehabilitation Medicine Board of Governors on April 30, 2018; by the National Institute on Disability, Independent Living, and Rehabilitation Research Review Committee on April 5, 2018; and by the AAN Institute Board of Directors on May 2, 2018.

This practice guideline was endorsed by the American Academy of Physical Medicine and Rehabilitation on April 4, 2018; by the American College of Surgeons Committee on Trauma on July 3, 2018; and by the Child Neurology Society on April 17, 2018.

This special article is published simultaneously in the Archives of Physical Medical Rehabilitation and Neurology. Neurology was responsible for peer review of this article.
Glossary

AAN = American Academy of Neurology; ACRM = American Congress of Rehabilitation Medicine; CI = confidence interval; CRS-R = Coma Recovery Scale–Revised; DoC = disorders of consciousness; DRS = Disability Rating Scale; FDG = fluorodeoxyglucose; MCS = minimally conscious state; TBI = traumatic brain injury; UWS = unresponsive wakefulness syndrome; VS = vegetative state.

This article presents practice guideline recommendations developed by the American Academy of Neurology (AAN), the American Congress of Rehabilitation Medicine (ACRM), and the National Institute on Disability, Independent Living, and Rehabilitation Research (see complete guideline at links. lww.com/WNL/A611). A companion article summarizes systematic review conclusions.1

Recommendations

Unless noted, recommendations apply to individuals with prolonged disorders of consciousness (DoC) (i.e., ≥28 days). Recommendation rationales are presented; tables summarize recommendations for adults (tables 1–3) and children (table 4).

Recommendation 1 rationale

Our systematic review highlights the complexities of caring for patients with prolonged DoC (i.e., ≥28 days) at every stage. Such patients may be misdiagnosed due to confounding neurologic deficits2 or inexperience in examining patients for subtle signs of consciousness.3 Accurate diagnosis is important to educate families about patients’ level of consciousness and function, inform prognostic counseling, and guide treatment decisions. Knowledge gaps often lead to overestimation or underestimation of prognosis by nonspecialists.4 In addition, patients with prolonged DoC frequently experience significant medical complications that can slow recovery and interfere with treatment interventions.3 In view of this risk, patients are likely to have a better chance for recovery if care is provided in a specialized setting managed by clinicians who are knowledgeable about the risks associated with DoC and are capable of initiating timely treatment. This is supported by findings from a large retrospective trauma registry, which found that cumulative mortality at 3 years postdischarge is significantly lower for patients discharged to home or inpatient rehabilitation facilities than those discharged to skilled nursing facilities, even after adjusting for covariates.6 Care for patients with prolonged DoC may benefit from a team of multidisciplinary rehabilitation specialists, including neurologists, psychologists, neuropsychologists, physiatrists, physical therapists, occupational therapists, speech pathologists, nurses, nutritionists, internists, and social workers.

Supplemental Data

Full text of guideline at: NPub.org/mSi8i

Recommendation 2 rationale

The range of physical and cognitive impairments experienced by individuals with severe DoC complicates diagnostic accuracy and makes it difficult to distinguish behaviors that are indicative of conscious awareness from those that are random and nonpurposeful. Interpretation of inconsistent behaviors or simple motor responses is particularly challenging. Fluctuations in arousal and response to command further confound the reliability of clinical assessment.7,8 Underlying central and peripheral impairments, such as aphasia, neuromuscular abnormalities, and sensory deficits, may also mask conscious awareness.9–11 Clinician reliance on nonstandardized procedures, even when the examination is performed by experienced clinicians,2,12,13 contributes to diagnostic error, which consistently hovers around 40%. Diagnostic error includes misdiagnosing the locked-in syndrome for vegetative state/unresponsive wakefulness syndrome (VS/UWS) and minimally conscious state (MCS).14,15 Accurate diagnosis of the level of consciousness has implications for prognosis and management.

Recommendation 2a rationale

In view of the range of clinical challenges to accurate and reliable diagnosis of DoC, standardizing the assessment of patients with DoC can assist in recognizing key diagnostic features that may be missed on ad hoc examinations.12,16 The validity and reliability of standardized neurobehavioral assessment scales for diagnosis of DoC subtype have been previously reviewed.17 Other techniques such as individualized quantitative behavioral assessment have been useful in distinguishing specific purposeful responses from generalized, nonpurposeful, or reflexive responses.18 On the basis of these findings, diagnostic accuracy may be enhanced by using standardized neurobehavioral assessment measures over qualitative bedside examination alone. If standardized assessments are used, those with the highest quality of evidence should be employed. A systematic review performed by ACRM recommended the Coma Recovery Scale–Revised (CRS-R),16 Wessex Head Injury Matrix,19 Sensory Modality Assessment and Rehabilitation Technique,20 Western Neurosensory Stimulation Protocol,21 Disorders of Consciousness Scale,22 and Sensory Stimulation Assessment Measure23 for use in clinical practice.17

Recommendation 2b rationale

While there is insufficient high-quality evidence to recommend the use of serial evaluations to improve diagnostic sensitivity and specificity, because of the inconsistency and variability of behavioral responses that is characteristic of
individuals with prolonged DoC, reliance on a single examination may contribute to greater risk of misdiagnosis. Multiple behavioral evaluations over time may improve diagnostic reliability and accuracy as compared with a single evaluation. Serial evaluations conducted by trained clinicians using a standardized, validated neurobehavioral assessment instrument have the potential to improve the reliability/validity of diagnosis. There are insufficient data to recommend a minimum duration of time for an assessment session or how often serial examinations should be performed. The frequency of serial standardized neurobehavioral examinations should be based on clinical judgment with consideration given to reported changes in arousal and responsiveness, the removal or cessation of diagnostic confounders, and the length of time since the last assessment.

**Recommendation 2c/2d rationale**

Patients with prolonged DoC may exhibit inconsistent or reduced behavioral responsiveness because of fluctuations in the level of arousal, systemic medical problems, secondary neurologic complications, and other adverse events (e.g., medication side effects). Level of consciousness cannot be assessed accurately during periods of low arousal. In patients who demonstrate fluctuations in wakefulness, efforts should be made to increase arousal level using protocols designed for this purpose (e.g., the CRS-R Arousal Facilitation Protocol) before assessing the level of consciousness. Identifying and treating conditions that impair neurologic functioning may also improve arousal and level of consciousness.

**Recommendation 2e/2f rationale**

Our systematic review identified that some electrophysiologic procedures (EMG thresholds for detecting response to motor commands, EEG reactivity, laser-evoked potential responses, and the Perturbational Complexity Index) possibly have value for distinguishing MCS from VS/UWS, generally to an only mildly important degree. There is insufficient evidence to support or refute the routine clinical use of functional neuroimaging or routine EEG or evoked response studies as clinically useful adjuncts to behavioral evaluations to detect conscious awareness in patients diagnosed with VS/UWS. In addition, functional imaging is not widely available and may not be clinically feasible in large numbers of patients. However, 2 reviewed studies identified fMRI changes in response to a word-counting task and an incorrect-minus-correct activation protocol in patients diagnosed with VS/UWS by the CRS-R (38%, 95% confidence interval [CI] 14%–69%, and 38%, 95% CI 23%–56%,

---

**Table 1** Recommendation statements for overall care and diagnosis for adults with a prolonged disorder of consciousness (DoC)

<table>
<thead>
<tr>
<th>Recommendation number</th>
<th>Recommendation statement and level</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Clinicians should refer patients with DoC who have achieved medical stability to settings staffed by multidisciplinary rehabilitation teams with specialized training to optimize diagnostic evaluation, prognostication, and subsequent management, including effective medical monitoring and rehabilitative care (Level B).</td>
</tr>
<tr>
<td>2a</td>
<td>Clinicians should use standardized neurobehavioral assessment measures that have been shown to be valid and reliable (such as those recommended by the ACRM) to improve diagnostic accuracy for the purpose intended (Level B based on importance of outcomes and feasibility).</td>
</tr>
<tr>
<td>2b</td>
<td>To reduce diagnostic error in individuals with prolonged DoC after brain injury, serial standardized neurobehavioral assessments should be performed with the interval of reassessment determined by individual clinical circumstances (Level B based on cogency, feasibility, and cost relative to benefit).</td>
</tr>
<tr>
<td>2c</td>
<td>Clinicians should attempt to increase arousal before performing evaluations to assess level of consciousness anytime diminished arousal is observed or suspected (Level B based on importance of outcomes).</td>
</tr>
<tr>
<td>2d</td>
<td>Clinicians should identify and treat conditions that may confound accurate diagnosis of a DoC prior to establishing a final diagnosis (Level B based on feasibility and cost).</td>
</tr>
<tr>
<td>2e</td>
<td>In situations where there is continued ambiguity regarding evidence of conscious awareness despite serial neurobehavioral assessments, or where confounders to a valid clinical diagnostic assessment are identified, clinicians may use multimodal evaluations incorporating specialized functional imaging or electrophysiologic studies to assess for evidence of awareness not identified on neurobehavioral assessment that might prompt consideration of an alternate diagnosis (Level C based on assessment of benefit relative to harm, feasibility, and cost relative to benefit).</td>
</tr>
<tr>
<td>2f</td>
<td>In situations where there is no behavioral evidence of consciousness on clinical examination but functional neuroimaging or electrophysiologic testing suggests the possibility of preserved conscious awareness, frequent neurobehavioral reevaluations may be conducted to identify emerging signs of conscious awareness (Level C based on feasibility) and decisions to reduce the intensity of rehabilitation treatment may be delayed for those individuals receiving active rehabilitation management (Level C based on variation in patient preferences and cost relative to net benefit), with the length of time over which these are done determined by an agreement between the treating clinician and the health care proxy given the lack of evidence to provide guidance.</td>
</tr>
</tbody>
</table>

Abbreviation: ACRM = American Congress of Rehabilitation Medicine.

*Level A is the strongest recommendation level and is denoted by use of the helping verb should. These recommendations are rare. Level B corresponds to the helping verb must. Such recommendations are more common, as the requirements are less stringent but are still associated with confidence in the rationale and a favorable benefit–risk profile. Level C corresponds to the helping verb may. These recommendations represent the lowest allowable recommendation level that the American Academy of Neurology considers useful within the scope of clinical practice and can accommodate the highest degree of practice variation.*
respectively).24,25 Research studying DoC populations overlapping with those in this guideline (i.e., cohorts including patients with a DoC for longer than 28 days but not confined exclusively to patients with prolonged DoC) suggests that some individuals without signs of awareness on behavior-based evaluations may have positive findings using other modalities, such as functional MRI, PET scans, or electrophysiologic studies. In 1 study26 of patients with VS/UWS based on standardized neurobehavioral assessment, functional neuroimaging studies (18F-fluorodeoxyglucose [FDG] PET, fMRI) performed at various times postinjury demonstrated evidence of brain activity compatible with at least minimal conscious awareness in approximately 32% of patients scanned using 18F-FDG PET or mental imagery fMRI or both (13/41; 95% CI 20%–47%), with 11F-FDG PET showing results consistent with MCS in 33% of patients diagnosed with VS/UWS by the CRS-R (12/36, 95% CI 20%–50%) and mental imagery fMRI showing results consistent with MCS in 11% (3/28, 95% CI 4%–27%). When using high-density EEG recordings assessing a combination of low-frequency power, EEG complexity, and information exchange in a population overlapping with that in this guideline, 25 of 75 recordings in patients in VS/UWS (33%, 95% CI 24%–45%) were classified as suggestive of MCS, with a greater recovery of consciousness in those categorized as MCS than VS/UWS on the EEG (11/50 VS vs 11/23 MCS, with 2 lost to follow-up; risk difference 26%, 95% CI 3%–47%).27

Although multimodal evaluations show promise in increasing sensitivity for detection of conscious awareness, these studies return negative findings in the majority of patients diagnosed with VS/UWS on behavioral assessment, and the exact link between these findings and consciousness remains unclear. Widespread use of multimodal imaging is unlikely to change the diagnosis in most patients diagnosed with VS/UWS. At
Coma Scale motor score. Withdrawal of life-sustaining therapy was more closely associated with the patient experiencing pain (Level B), regardless of level of consciousness. Clinicians should counsel families that there is uncertainty regarding the degree of pain and suffering that may be experienced by patients with a DoC (Level B).

Clinicians should counsel families that there are no established therapies for children with a prolonged DoC (Level B).

Clinicians should counsel families about the limitations of existing evidence concerning treatment effectiveness and the potential risks and harms associated with interventions that lack evidentiary support (Level B). When discussing nonvalidated treatments, clinicians should provide evidence-based information regarding the projected benefits and risks of a particular treatment and the level of uncertainty associated with the proposed intervention, keeping in mind that families and caregivers are often in distress and vulnerable (Level B). Clinicians should counsel families that, in many cases, it is impossible to discern whether improvements observed early in the course of recovery were caused by a specific intervention or spontaneous recovery (Level B).

Clinicians should treat confounding conditions, increase arousal prior to diagnostic assessments, use valid and reliable standardized behavioral assessments (particularly those targeting pediatric populations), and conduct serial assessments to improve diagnostic accuracy in children with prolonged DoC (Level B).

Clinicians should counsel families that there are no established therapies for children with a prolonged DoC (Level B).

Clinicians should counsel families that the natural history and prognosis of children with prolonged DoC is not well-defined and that there are no current evaluations established to improve prognostic accuracy in this population (Level B).
In the current systematic review, no study evaluated the prognosis of patients with traumatic VS/UWS after 12 months of injury. One Class II study mixing patients with traumatic and nontraumatic VS/UWS found that none of these patients in VS/UWS 12 months after onset improved when assessed at 2, 3, 4, and 5 years postinjury (1 lost to follow-up, 9 died, and 2 remained in VS/UWS), but due to the small sample size, CIs for the possibility of improving were wide (0%, 95% CI 0%–24%).

Recent studies suggest that some patients with prolonged nontraumatic VS/UWS may experience ongoing recovery after 3 months. Meta-analyses performed in this systematic review found it is possible that 17% (95% CI 5%–30%) will recover consciousness (emerge from VS/UWS) at 6 months. After 6 months, it is possible that an estimated 7.5% (95% CI 0%–24%) may recover consciousness. In one study of prolonged anoxic vegetative state included in the systematic review, of the 9 of 43 recovering responsiveness, 2 recovered between 3 and 6 months, 3 recovered at 6–12 months, and 4 recovered at 12–24 months. Of the 2 individuals emerging from MCS, 1 patient recovered consciousness at 16 months and emerged from MCS at 18 months and the other recovered consciousness at 22 months and emerged from MCS at 25 months; both remained severely disabled. Of 41 patients who remained in VS/UWS at 6 months, 7 additional patients recovered consciousness before 24 months (17%, 95% CI 9%–31%). The natural history of nontraumatic VS/UWS is likely tied to the underlying etiology, with nontraumatic VS/UWS related to a specific insult (e.g., anoxic injury, ischemia) different from that relating to ongoing neurodegeneration.

Additional evidence suggests that late transition to MCS from VS/UWS may occur in as many as 20% of patients who meet permanence criteria. One study followed 50 patients who remained unconscious for a mean of 11.1 (±4.8) months after traumatic or nontraumatic brain injury and reported that 10 patients (7 traumatic, 3 nontraumatic) recovered consciousness between 1 and 5 years postonset. A second study followed 108 patients with TBI across a 5-year interval, all of whom failed to recover command-following during the course of inpatient rehabilitation. Among the 17 patients who were still unable to follow commands at 12 months postonset, 8 (47.0%) regained this ability between 1 and 5 years postinjury.

Although the majority of patients who remain in VS/UWS across the first 3 (after nontraumatic) and 12 months (after traumatic) postinjury will remain in this condition permanently, a substantial minority will recover consciousness beyond this time frame. While most of these patients will be left with severe disability, functional outcome ratings indicate that some will regain the ability to communicate reliably, perform self-care activities, and interact socially.

In view of these findings, continued use of the term permanent VS is not justified. Use of this term implies irreversibility,
which is not supported by the current research and has implications for family counseling, decision-making, and the ethics of the field. The guideline panel suggests that the term permanent VS be replaced by the term chronic VS to indicate the stability of the condition (in keeping with other diseases that have a chronic phase). This should be accompanied by a description of the current duration of the VS/UWS, as evidence supports a decreasing likelihood of recovery with longer duration of unresponsiveness. Because most patients with late recovery of consciousness will remain fully or partially dependent upon others for activities of daily living, prognostic counseling should emphasize the need for long-term care and specify the type of supportive care required.

**Recommendation 8 rationale**

Systematic review evidence showed that in patients with prolonged DoC, those diagnosed with MCS within the first 5 months of injury have a more favorable long-term prognosis for functional recovery than those diagnosed with VS/UWS. Long-term prognosis is also more favorable in patients in MCS who have sustained traumatic vs nontraumatic brain injury. The evidence reviewed does not clearly support or refute age and time postinjury as prognostic features.

As described in the rationale for recommendation 3 above, evidence from the systematic review identified that individuals with a DoC at 1 month postinjury may still attain functionally significant recovery after 1 year postinjury, with additional longitudinal studies showing that approximately 20% of patients recover to the level where they could return to work or school.

**Recommendation 9 rationale**

Patients with prolonged DoC may have a prolonged recovery over months to years, and many will remain severely disabled. Employment and personal finances in the short term and the long term will be significantly affected, and these effects will have implications for family members. Patients and families benefit from planning in advance for an expected prolonged recovery.

**Recommendation 10 rationale**

See rationale for recommendation 7.

**Recommendation 11 rationale**

Preexpressed wishes of patients with prolonged DoC and values of families of persons with prolonged DoC can be highly variable. Values may also change over the course of illness. Personal values should be identified early and need to be reassessed over time when making decisions regarding care for individuals with prolonged DoC.

**Recommendation 12 rationale**

Complication rates are high in patients with prolonged DoC and negatively affect morbidity and mortality. It is important that clinicians remain vigilant to medical complications in the short term to facilitate their early identification and to help optimize long-term outcomes. The most common complications in patients with prolonged DoC include agitation/aggression, hypertonia, sleep disturbance, and urinary tract infections. Other, more severe complications, such as hydrocephalus, pneumonia, and paroxysmal sympathetic hyperactivity, can disrupt rehabilitation efforts, as they often require rehospitalization. Strategies for early detection and rapid management of complications include daily physician rounds, 24-hour specialty physician coverage, on-site availability of diagnostic resources, and timely access to specialty consultations.

**Recommendation 13 rationale**

The potential to experience pain and suffering is an issue frequently raised with respect to treatment, ethical, and legal questions in individuals with DoC. Some studies using functional imaging indicate that brain activation in networks supporting pain perception is lower in patients diagnosed with VS compared with those in MCS and conscious controls, suggesting that patients in VS lack capacity for full pain awareness. Other studies suggest that the relationship between level of consciousness and pain perception is unclear. Accurate assessment of pain and suffering in individuals with DoC is limited by challenges in accurately diagnosing pain due to the level of consciousness and conflicting evidence regarding the potential of patients in VS or MCS to experience pain and suffering. Clinicians should be cautious in making definitive conclusions about pain and suffering in individuals with DoC.

**Recommendation 14 rationale**

Amantadine (100–200 mg twice daily), when administered over a period of 4 weeks in patients between 16 and 65 years old with traumatic DoC who are between 4 and 16 weeks of injury, probably hastens functional recovery in the early stages. Faster recovery reduces the burden of disability, lessens health care costs, and minimizes psychosocial stressors in patients and caregivers.

**Recommendation 15 rationale**

Most therapies proposed for treating patients with DoC (e.g., hyperbaric oxygen, nutraceuticals, stem cell therapies, primrose oil) have insufficient evidence to support or refute their use, and many have associated risks. Families may pursue these treatments in the absence of evidence because they are desperate for ways to help their loved one and interventions supported by high-quality evidence are sparse. Counseling families about treatment effectiveness is complicated by the difficulties inherent in determining whether improvements observed early in the course of recovery are related to interventions or due to spontaneous recovery.

**Recommendation 16 rationale**

No evidence was identified regarding the diagnosis of children with prolonged DoC. In the absence of pediatric-specific evidence, it is reasonable to apply the diagnostic recommendations for adult populations that address the treatment of confounding conditions to improve diagnosis, the
importance of increasing arousal prior to diagnostic assessments, using valid and reliable standardized behavioral assessments, and conducting serial assessments to children with DoC.

**Recommendation 17 rationale**
The natural history of DoC in children is not well-defined. In children with prolonged DoC, traumatic etiology is possibly associated with a better chance of recovery, as is the absence of posttraumatic autonomic dysfunction. Posttraumatic hyperthermia may be associated with a worse outcome. No other evidence was identified.

**Recommendation 18 rationale**
No identified therapeutic studies enrolled pediatric populations. The only therapeutic intervention shown to have efficacy in adults (16–65 years) is amantadine. A retrospective case-controlled study of amantadine use in patients with TBI reported that 9% of children taking this treatment had side effects, but methodologic concerns limit therapeutic conclusions from this study.

**Author contributions**
Dr. Giacino: study concept and design, acquisition, analysis, and interpretation of data, drafting/revising the manuscript, critical revision of the manuscript for important intellectual content, study supervision. Dr. Katz: study concept and design, acquisition, analysis, and interpretation of data, drafting/revising the manuscript, critical revision of the manuscript for important intellectual content. Dr. Schiff: study concept and design, acquisition, analysis, and interpretation of data, drafting/revising the manuscript, critical revision of the manuscript for important intellectual content. Dr. Whyte: study concept and design, acquisition, analysis, and interpretation of data, drafting/revising the manuscript, critical revision of the manuscript for important intellectual content. Dr. Ashman: acquisition, analysis, and interpretation of data, critical revision of the manuscript for important intellectual content. Dr. Ashwal: study concept and design, acquisition, analysis, and interpretation of data, drafting/revising the manuscript, critical revision of the manuscript for important intellectual content. Dr. Barbano: acquisition, analysis, and interpretation of data, drafting/revising the manuscript, critical revision of the manuscript for important intellectual content, study supervision. Dr. Hammond: acquisition, analysis, and interpretation of data, drafting/revising the manuscript, critical revision of the manuscript for important intellectual content. Dr. Laureys: acquisition, analysis, and interpretation of data, drafting/revising the manuscript, critical revision of the manuscript for important intellectual content. Dr. Ling: acquisition, analysis, and interpretation of data, drafting/revising the manuscript, critical revision of the manuscript for important intellectual content. Dr. Nakase-Richardson: acquisition, analysis, and interpretation of data, drafting/revising the manuscript, critical revision of the manuscript for important intellectual content. Dr. Seel: acquisition, analysis, and interpretation of data, drafting/revising the manuscript, critical revision of the manuscript for important intellectual content. Dr. Yablon: acquisition, analysis, and interpretation of data, drafting/revising the manuscript, critical revision of the manuscript for important intellectual content. Dr. Gronseth: acquisition, analysis, and interpretation of data, drafting/revising the manuscript, critical revision of the manuscript for important intellectual content. T. Getchius: acquisition, analysis, and interpretation of data. Dr. Armstrong: acquisition, analysis, and interpretation of data, drafting/revising the manuscript, critical revision of the manuscript for important intellectual content, study supervision.

**Study funding**
This practice guideline was funded by the American Academy of Neurology (AAN), the American Congress of Rehabilitation Medicine, and the National Institute on Disability, Independent Living, and Rehabilitation Research. Authors who serve or served as AAN subcommittee members (E.J.A., S.A., R.B., G.S.G.) or as methodologists (M.J.A., G.S.G.), or who were AAN staff members (T.S.D.G.), were reimbursed by the AAN for expenses related to travel to subcommittee meetings where drafts of manuscripts were reviewed.

**Disclosure**
J. Giacino has received funding for travel from the US Department of Defense for a meeting related to the TBI Endpoint Development Project; from the National Institute on Neurological Disorders and Stroke (NINDS) of the NIH for a meeting related to the Transforming Research and Clinical Knowledge in Traumatic Brain Injury study; from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) for the Traumatic Brain Injury Model Systems Project Directors meeting; from the American Academy of Physical Medicine and Rehabilitation, the One Mind Foundation, and the James S. McDonnell Foundation for a meeting related to the Recovery of Consciousness After Severe Brain Injury study; from the Barbara Epstein Foundation; and from the International Brain Injury Association; has received a cash donation from the Epstein Foundation for a hospital clinical program that he directs and for serving on a team that provided clinical consultation services to an overseas patient who sustained severe brain injury; has served as an editor for the Journal of Head Trauma Rehabilitation; has received honoraria from the One Mind Foundation, Holy Cross Hospital (Surrey, UK), HealthSouth Braintree Hospital, Western Michigan Brain Injury Network, George Washington University Medical School, Association of Academic Physiatrists, Mayo Clinic, Kennedy-Krieger Institute, and Magill’s Medical Guide; performs clinical procedures as 10% of his clinical effort in his role as Director of Spaulding Rehabilitation Network Disorders of Consciousness Program and neuroimaging as a principal investigator on 2 neuroimaging studies for 30% of his research effort; received financial support from the NIH NINDS for Central Thalamic Stimulation for Traumatic Brain Injury, US Department of
Defense for TBI Endpoint Development Project, the Huperzine A for the Treatment of Cognitive, Mood and Functional Deficits After Moderate and Severe TBI study, the Injury and Traumatic Stress (INTRuST) Consortium Neuroimaging Acquisition and Archival study, the NIDILRR for the Spaulding Harvard–Traumatic Brain Injury Model System and for Multicenter Evaluation of Memory Remediation after Traumatic Brain Injury with Donepezil, the NINDS for Transforming Research and Clinical Knowledge in Traumatic Brain Injury study, James S. McDonnell Foundation for Study of Recovery of Consciousness After Severe Brain Injury, Barbara Epstein Foundation, and the Spaulding Rehabilitation Hospital Department of Physical Medicine and Rehabilitation; and has acted as a witness with regard to a legal proceeding. D. Katz has received royalties from Demos for Brain Injury Medicine, 2013, and from Lash Publications; has received honoraria for speaking at HealthSouth/Encompass Health Medical Directors’ Conference, various grand rounds on topics related to DoC, including Harvard Longwood Neurology, Providence VA Hospital, Tufts Medical Center, Baystate Medical Center, and University of Massachusetts Medical Center, and for service as Chair, External Scientific Advisory Board, VA Rehabilitation Research and Development TBI Center of Excellence, Boston; has given expert testimony in several legal cases involving patients with DoC after brain injury; has received travel support for talks and conferences on DoC from organizations, including World Federation of Neurorehabilitation, International Brain Injury Association, and Moody Foundation/Galveston Brain Injury Conference; received a stipend as medical director of the Acquired Brain Injury Program at Braintree Rehabilitation Hospital from HealthSouth; received compensation for less than 10% of his clinical effort for consultations on patients with DoC; and received support from efforts on NIDILRR-funded projects on DoC. N. Schiff serves on an advisory board for Intelect Medical Inc. and Enspire DBS, Inc. (Cleveland); is listed as inventor for multiple patents held by Cornell University; receives royalties for Plum and Posner’s Stupor and Coma, Oxford University Press; and holds 0.25% stock option in Enspire DBS, Inc. (no current value). J. Whyte served on a scientific advisory board for INTRuST; received funding for travel and honoraria from several noncommercial institutions for academic lectures; performs diagnostic behavioral assessments of patients with DoC as 10% of his clinical effort; received financial support from the NIH, the NIDILRR, and the Patient-Centered Outcomes Research Institute; and has given expert testimony with regard to a patient with DoC. E. Ashman served as Level of Evidence associate editor for Neurology® from 2011 to 2013; provided uncompensated medical-legal reviews for US Air Force legal proceedings as part of his active-duty responsibilities until 2012; received funding from the AAN to attend Guideline Development, Dissemination, and Implementation Subcommittee meetings as a subcommittee member and as an ex officio member through January 2018; and has been selected to serve on the editorial board of Neurology: Clinical Practice starting April 2018. S. Ashwal served on a medical advisory board for the Tuberous Sclerosis Association; serves as chief of the Division of Child Neurology, Department of Pediatrics, Loma Linda University School of Medicine; receives royalties for Pediatric Neurology: Principles and Practice, 6th ed.; and received financial support from the NIH NINDS for research on pediatric traumatic brain injury and for use of advanced imaging for detecting neural stem cell migration after neonatal HII in a rat pup model. R. Barbano has served as the associate editor for Neurology: Clinical Practice; has received compensation from law firms and insurance companies for independent medical records reviews and examinations; holds stock options from Visual Dx, Inc.; served on a speakers bureau for Allergan Inc.; and receives research support from the NIH Office of Rare Diseases Research via the Dystonia Coalition, unrelated to the content of this guideline. His spouse has received an NIH grant unrelated to the content of this guideline. F. Hammond is a member of the ACRM Disorders of Consciousness Task Force; served on the US Department of Defence INTRuST Scientific Advisory Council and Avanir Prism II Study Steering Committee; has received royalties from Demos Publishing and Lash Publishing; has received financial support for research from the NIDILRR; holds stock in AbbVie Inc., Amgen Inc., AstraZeneca Plc, Edwards Lifesciences, GW Pharmaceuticals Plc, Intuitive Surgical Inc., Konink Logistics Inc., Merck & Co. Inc., Pfizer Inc., Sanofi, Thermo Fisher Scientific Inc., UnitedHealth Group, and Zoetis Inc.; and has given legal testimony and acted as legal consultant in legal proceedings on the care needs of individuals with brain injury. S. Laureys performs fMRI, PET, and EEG as 20% of his clinical effort; received funding from noncommercial institutions such as Belgium’s National Fund for Scientific Research, European Commission, Collaborative European NeuroTrauma Effectiveness Research in TBI Project, Human Brain Project, James McDonnell Foundation, European Space Agency, "Fondazione Europea di Ricerca Biomedica,” BIAL Foundation, Belspo, Wallonia-Brussels Federation Concerted Research Action, and Mind Science Foundation; has served as an editor for Progress in Brain Research and Current Opinion in Neurology; is a member of the Belgian Advisory Committee on Bioethics and Belgian Brain Council and board member of the International Brain Injury Association; elected delegate of the European Academy of Neurology; President of the Association for the Scientific Study of Consciousness and chair of the World Federation of Neurology Applied Research Group on Coma and Disorders of Consciousness; receives royalties for The Neurology of Consciousness, Elsevier, 2015; has given expert testimony with regard to legal cases in Belgium and the Netherlands; and has prepared an affidavit and acted as a witness for legal proceedings in Belgium. G. Ling has served on scientific advisory boards for the NIH National Center for Advancing Translational Sciences (NCATS), the Veterans Administration National Research Advisory Council, Biogen, Facebook B8, KnoLimits, LLC, NED Biosystems, and Camden Partners; served on the board of directors of BioElectron Technologies Corporation (aba Edison Pharmaceuticals); received funding for travel from NIH NCATS, Facebook B8, Edison...
Pharmaceuticals, KnoLimits, LLC, and Camden Partners; served as a guest editor for *Seminars in Neurology* and *Experimental Neurology*; holds a patent (U.S. Patent 7,195,959-B2) with Campbell, M., for a method and apparatus used for monitoring the efficacy of fluid resuscitation; received honoraria from Medtronic, National Defense University (Japan), Sanofi Aventis, Science Teachers, and University of Panama; has been employed by SunQ LLC, DsRS Ling, and Center for Brain Health; and holds stock in BioElectron Technologies Corporation (_NONE(aba Edison Pharmaceuticals), Host Response, NED Biosystems, Camden Partners, Pfizer, and Merck. R. Nakase-Richardson has received financial compensation for travel for speaking at the University of Mississippi Medical Center, New York University, Mayo Clinic, and University of Alabama, Birmingham; and has received research support from General Dynamics Health Solutions from the Defense and Veterans Brain Injury Center within the Defense Health Agency, US Department of Veterans Affairs Health Services Research and Development, Department of Veterans Affairs Rehabilitation Research and Development, and Patient-Centered Outcomes Research Institute. R. Seel has served as both a member and the Chair of the ACRM Disorders of Consciousness Task Force and the ACRM Evidence and Practice Committee; served as an editor for the *Journal of Head Trauma Rehabilitation*; holds a patent on an electronic driving coach; receives publishing royalties from Pearson; received honoraria for several university-based talks; received payment as a grant reviewer for the Department of Defense Congressionally Directed Medical Research Programs and US Department of Veterans Affairs Rehabilitation Research and Development Service; and has received research funding from the NIDILRR, the NIH, the Centers for Disease Control and Prevention, the Craig H. Neilsen Foundation, and the Shepherd Center Foundation. S. Yablon has served on scientific advisory boards for Allergan Inc., Flowonix Medical Inc., Ipsen Pharma, Medtronic Inc., and Merz Pharmaceuticals GmbH; received travel-related funding from Allergan Inc., Ipsen Pharma, Medtronic Inc., and Merz Pharmaceuticals GmbH; served as associate editor for the journal *PM&R* and on the editorial advisory board for the Baylor University Medical Center Proceedings; has received honoraria for presentations given during scientific meetings sponsored or cosponsored by Allergan Inc. and Merz Pharmaceuticals GmbH; performs botulinum neurotoxin procedures for treatment of focal spastic hypertonia (<10% of clinical effort); has received financial research support from Medtronic Inc. and research support from the NIDILRR; and has given expert testimony and acted as legal consultant in legal proceedings. T. Getchius has received financial compensation for travel to speak at the University of Louisville mTBI conference and the New York Academy of Medicine E-GAPPS conferences; has been serving as the vice-chair of the Council of Medical Specialty Societies Clinical Practice Guideline Component Group from November 2013 to present; has received research support (all monies directed to the AAN) from the Centers for Disease Control and Prevention for a grant for muscular dystrophy guideline development, dissemination, and implementation; and is a past employee of the AAN. G. Gronseth serves on the Neurology Now editorial advisory board and receives financial support for serving as chief evidence-based methodologist for the AAN. M. Armstrong serves on the Level of Evidence editorial board for *Neurology* (but is not compensated financially) and serves as an evidence-based medicine methodologist for the AAN. Go to Neurology.org/N for full disclosures.

**Disclaimer**

Clinical practice guidelines, practice advisories, systematic reviews, and other guidance published by the American Academy of Neurology (AAN) and its affiliates and the American Congress of Rehabilitation Medicine (ACRM) are assessments of current scientific and clinical information provided as an educational service. The information (1) should not be considered inclusive of all proper treatments, methods of care, or as a statement of the standard of care; (2) is not continually updated and may not reflect the most recent evidence (new evidence may emerge between the time information is developed and when it is published or read); (3) addresses only the questions specifically identified; (4) does not mandate any particular course of medical care; and (5) is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. The AAN and ACRM specifically disclaim any warranties of merchantability or fitness for a particular use or purpose. The AAN and ACRM assume no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions. This document does not reflect the official policy or opinions of the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) or the US Health and Human Services Department (HSS) and does not constitute an endorsement by NIDILRR, HHS, or other components of the federal government.

**Conflict of interest**

The American Academy of Neurology (AAN) and the American Congress of Rehabilitation Medicine (ACRM) are committed to producing independent, critical, and truthful clinical practice guidelines (CPGs). Significant efforts are made to minimize the potential for conflicts of interest to influence the recommendations of this CPG. To the extent possible, the AAN and the ACRM keep separate those who have a financial stake in the success or failure of the products appraised in the CPGs and the developers of the guidelines. Conflict of interest forms were obtained from all authors and reviewed by an oversight committee prior to project initiation. The AAN and the ACRM limit the participation of authors with substantial conflicts of interest. The AAN and ACRM forbid commercial participation in, or funding of, guideline projects. Drafts of the


Practice guideline update recommendations summary: Disorders of consciousness: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research
Neurology published online August 8, 2018
DOI 10.1212/WNL.000000000005926

This information is current as of August 8, 2018
<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>Updated Information &amp; Services including high resolution figures, can be found at: <a href="http://n.neurology.org/content/early/2018/08/08/WNL.0000000000005926.full">http://n.neurology.org/content/early/2018/08/08/WNL.0000000000005926.full</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Supplementary material can be found at: <a href="http://n.neurology.org/content/suppl/2018/09/10/WNL.0000000000005926.DC1">http://n.neurology.org/content/suppl/2018/09/10/WNL.0000000000005926.DC1</a></td>
</tr>
<tr>
<td>Citations</td>
<td>This article has been cited by 7 HighWire-hosted articles: <a href="http://n.neurology.org/content/early/2018/08/08/WNL.0000000000005926.full##otherarticles">http://n.neurology.org/content/early/2018/08/08/WNL.0000000000005926.full##otherarticles</a></td>
</tr>
<tr>
<td>Subspecialty Collections</td>
<td>This article, along with others on similar topics, appears in the following collection(s):</td>
</tr>
<tr>
<td></td>
<td>All Clinical Neurology <a href="http://n.neurology.org/cgi/collection/all_clinical_neurology">http://n.neurology.org/cgi/collection/all_clinical_neurology</a></td>
</tr>
<tr>
<td></td>
<td>All clinical neurophysiology <a href="http://n.neurology.org/cgi/collection/all_clinical_neurophysiology">http://n.neurology.org/cgi/collection/all_clinical_neurophysiology</a></td>
</tr>
<tr>
<td></td>
<td>All Pediatric <a href="http://n.neurology.org/cgi/collection/all_pediatric">http://n.neurology.org/cgi/collection/all_pediatric</a></td>
</tr>
<tr>
<td></td>
<td>Brain trauma <a href="http://n.neurology.org/cgi/collection/brain_trauma">http://n.neurology.org/cgi/collection/brain_trauma</a></td>
</tr>
<tr>
<td></td>
<td>Plasticity <a href="http://n.neurology.org/cgi/collection/plasticity">http://n.neurology.org/cgi/collection/plasticity</a></td>
</tr>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a></td>
</tr>
</tbody>
</table>

*Neurology®* is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2018 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.